These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 16525495)
1. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells. von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Jedema I; Mulder A; Willemze R; Falkenburg JH Leukemia; 2006 Jun; 20(6):1040-6. PubMed ID: 16525495 [TBL] [Abstract][Full Text] [Related]
2. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403 [TBL] [Abstract][Full Text] [Related]
3. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; Barbui AM; van Egmond HM; Strijbosch MP; Kester MG; Marijt WA; Goulmy E; Willemze R; Falkenburg JH Leukemia; 2004 Apr; 18(4):798-808. PubMed ID: 14973499 [TBL] [Abstract][Full Text] [Related]
4. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. Faber LM; van der Hoeven J; Goulmy E; Hooftman-den Otter AL; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH J Clin Invest; 1995 Aug; 96(2):877-83. PubMed ID: 7635982 [TBL] [Abstract][Full Text] [Related]
5. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon. Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352 [TBL] [Abstract][Full Text] [Related]
6. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886 [TBL] [Abstract][Full Text] [Related]
7. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791 [TBL] [Abstract][Full Text] [Related]
8. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616 [TBL] [Abstract][Full Text] [Related]
9. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280 [TBL] [Abstract][Full Text] [Related]
10. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Falkenburg JH; Wafelman AR; Joosten P; Smit WM; van Bergen CA; Bongaerts R; Lurvink E; van der Hoorn M; Kluck P; Landegent JE; Kluin-Nelemans HC; Fibbe WE; Willemze R Blood; 1999 Aug; 94(4):1201-8. PubMed ID: 10438707 [TBL] [Abstract][Full Text] [Related]
11. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation. Román J; Alvarez MA; Torres A Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600 [TBL] [Abstract][Full Text] [Related]
12. Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/CD3+ lymphocytes. Voogt PJ; Falkenburg JH; Fibbe WE; Veenhof WF; Hamilton M; Van Krimpen BA; Bolhuis RL J Immunol; 1989 Mar; 142(5):1774-80. PubMed ID: 2521886 [TBL] [Abstract][Full Text] [Related]
13. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882 [TBL] [Abstract][Full Text] [Related]
14. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Wang ZD; Li D; Huang XJ Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687 [TBL] [Abstract][Full Text] [Related]
15. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267 [TBL] [Abstract][Full Text] [Related]
16. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia. Gardiner N; Lawler M; O'Riordan JM; Duggan C; De Arce M; McCann SR Bone Marrow Transplant; 1998 Apr; 21(7):711-9. PubMed ID: 9578312 [TBL] [Abstract][Full Text] [Related]
17. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118 [TBL] [Abstract][Full Text] [Related]
18. Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Jiang YZ; Kanfer EJ; Macdonald D; Cullis JO; Goldman JM; Barrett AJ Bone Marrow Transplant; 1991 Oct; 8(4):253-8. PubMed ID: 1756322 [TBL] [Abstract][Full Text] [Related]
19. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011 [TBL] [Abstract][Full Text] [Related]
20. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. Marijt WA; Kernan NA; Diaz-Barrientos T; Veenhof WF; O'Reilly RJ; Willemze R; Falkenburg JH Bone Marrow Transplant; 1995 Jul; 16(1):125-32. PubMed ID: 7581111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]